Tapentadol results in less deterioration of gastrointestinal function and symptoms than standard opioid therapy in healthy male volunteers.
Esben Bolvig MarkRasmus Wiberg NedergaardTine Maria HansenThomas Dahl NissenJens Brøndum FrøkjærS Mark ScottSøren Schou OlesenAsbjørn Mohr DrewesPublished in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2021)
In this mechanistic study, tapentadol caused significantly less colonic dysmotility and gastrointestinal side effects as compared with oxycodone in equianalgesic doses.